Shares of Zoetis Inc (NYSE:ZTS) have been assigned a consensus recommendation of “Buy” from the twenty research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $80.28.
ZTS has been the subject of a number of research analyst reports. Cowen set a $80.00 price target on Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. UBS Group reaffirmed a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a report on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 price target on Zoetis and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price target (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd.
In other news, insider Roman Trawicki sold 8,568 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $83.10, for a total transaction of $712,000.80. Following the completion of the transaction, the insider now directly owns 11,457 shares in the company, valued at approximately $952,076.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,569 shares of company stock valued at $8,594,429. Corporate insiders own 0.31% of the company’s stock.
Several institutional investors have recently bought and sold shares of ZTS. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Zoetis during the 4th quarter worth about $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at approximately $114,000. We Are One Seven LLC acquired a new position in shares of Zoetis in the 4th quarter valued at approximately $120,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the period. Finally, Premia Global Advisors LLC acquired a new position in shares of Zoetis in the 4th quarter valued at approximately $122,000. Institutional investors own 92.45% of the company’s stock.
Zoetis (NYSE:ZTS) traded up $0.18 during trading on Friday, hitting $84.87. The company had a trading volume of 1,087,529 shares, compared to its average volume of 2,821,288. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.85 and a quick ratio of 2.55. Zoetis has a fifty-two week low of $52.25 and a fifty-two week high of $85.54. The company has a market capitalization of $40,931.15, a PE ratio of 48.39, a price-to-earnings-growth ratio of 1.89 and a beta of 0.97.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business posted $0.47 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. equities analysts predict that Zoetis will post 3.04 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be given a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.59%. Zoetis’s payout ratio is 28.57%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.